Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Q1 2025 Earnings Presentation
23 slides from Innate Pharma Sa Class A's earnings presentation, May 13, 2025
Slide 1: Q1 2025 Business Update and Financial Results
Q1 2025 Business Update and Financial Results 13 May 2025
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Conference call agenda
Q1 2025 Business Update and Financial Results Conference call agenda Strategic Overview and Outlook Jonathan Dickinson Chief Executive Officer, Chairman of the Executive Board ANKET® & ADC Yannis Morel Chief Operating Officer Clinical Pipeline Progress Sonia Quaratino Chief Medical Officer Upcoming
Slide 4: 2025: Focus on Strategic Growth Pillars
2025: Focus on 3 Strategic Growth Pillars NK-cell engagers Antibody Drug Conjugates Current Late-Stage Assets • IPH6501 (CD20) ANKET® Phase 1 • IPH4502 (Nectin-4) IND cleared, • Lacutamab positive Phase 2 data, Phase 1 FPI Jan 2025 FDA feedback on next steps, • IPH6101 (CD123) ANKET ® Phase 2 Partne
Slide 5: A Robust Pipeline of Innovative, Differentiated Proprietary & Partnered Assets
A Robust Pipeline of Innovative, Differentiated Proprietary & Partnered Assets Pre-Clinical Phase 1 Phase 2 Phase 3 IPH67 IPH5301 (CD73) Lacutamab (KIR3DL2) Monalizumab (NKG2A) Undisclosed, solid tumor Solid tumors CTCL Unresectable Stg III NSCLC IPH81 IPH6501 (CD20-IL2v) Lacutamab (KIR3DL2) Undiscl
Slide 6: Innate Pharma and Sanofi strengthens relationship via strategic equity investment
Innate Pharma and Sanofi strengthens relationship via strategic equity investment Collaboration and License (from July 1st) New Shareholder (as of April 25th) • 2 molecules under license plus one option on one • €15m equity investment additional target: Number of shares of Innate: 9.05% ✓ IPH6401/SA
Slide 7: Our journey at ASCO 2025: Driving the Future of Cancer Care
Our journey at ASCO 2025: Driving the Future of Cancer Care Lacutamab IPH4502 TELLOMAK Phase 2 trial long-term follow-up data Trial in Progress: Phase 1 in advanced solid tumors Abstract TPS3159 Sézary syndrome June 2, 2025 – 1:30 – 4:30 PM CDT Abstract 2522 June 2, 2025 – 1:30 – 4:30 PM CDT Monaliz
Slide 8: ANKET & ADC
ANKET® & ADC Yannis Morel Chief Operating Officer 8
Slide 9: IPH6501: Innate's lead Proprietary ANKET, a novel CD20 targeted tetra-specific NK Cell Engager
IPH6501: Innate’s lead Proprietary ANKET®, a novel CD20 targeted tetra-specific Natural Killer Cell Engager targeting B-Cells IL-2v Tumor Associated Antigen • Provides proliferation signal targeted to NK cells • CD20 TAG NKp46 binder • NK cell activating receptor • Most specific marker of human NK c
Slide 10: IPH6501: depletes autologous CD20+ B cells with greater efficacy and lower cytokine induction
IPH6501: depletes autologous CD20+ B cells from HD with greater efficacy and lower induction of pro-inflammatory cytokines than a CD20-TCE Stronger B cell depletion Less pro-inflammatory cytokines IPH6501 CD20-TCE IC-NKCE-IL2v Demaria et al., Science Immunology 2024 10
Slide 11: IPH4502: A novel and differentiated Nectin-4 DAR8 exatecan ADC
ADC IPH4502: A novel and differentiated Nectin-4 DAR8 exatecan ADC Phase 1 underway Payload Exatecan, Binder a Topoisomerase I inhibitor Proprietary humanized • Active in EV/MMAE-resistant models anti-Nectin-4 Antibody • Higher Bystander Effect than EV, • High affinity leading to stronger activity i
Slide 12: IPH4502 overcomes EV resistance in a UC PDX tumor model
ADC IPH4502 overcomes EV resistance in a UC PDX tumor model Repetitive EV treatments EV-sensitive EV-resistant PDX model PDX model Nectin-4 MDR1 Nectin-4 MDR1 H-score: 200 H-score: 200 Vehicle IPH4502 4 mg/kg EV 4 mg/kg Treatment EV IPH4502 EV IPH4502 2000 2000 2000 2000 1000 1000 1000 1000 0 0 0 0
Slide 13: IPH4502 shows anti-tumor activity in PDX models from various indications
ADC IPH4502 shows anti-tumor activity in PDX models from various indications HNSCC TNBC Esophageal cancer Nectin-4 Nectin-4 Nectin-4 H-score: 160 H-score: 200 H-score: 125 Vehicle IPH4502 4 mg/kg IPH4502 10 mg/kg EV 4 mg/kg Treatment 3000 3000 1500 Tumor volume (mm3) Tumor volume (mm3) Tumor volume
Slide 14: IPH4502 exhibits superior in vivo anti-tumor activity vs. benchmarks in low Nectin-4 CDX model
IPH4502 exhibits superior in vivo anti-tumor activity vs. benchmarks in low Nectin-4 CDX model Nectin-4high breast cancer CDX model (SUM190-PT; ABC~400,000) IPH4502 LY EV Nectin-4 Vehicle Tumor volume (mm3) 1500 1500 1500 IPH4502 1000 1000 1000 LY EV 500 500 500 Treatment 0 0 0 0 10 20 30 40 50 0 10
Slide 15: Pipeline Progress
Pipeline Progress Sonia Quaratino Chief Medical Officer 15
Slide 16: Proprietary key clinical pipeline progress
Proprietary key clinical pipeline progress Key clinical pipeline IPH6501 (CD20-IL2v) Phase 1 Phase 1 IPH4502 (Nectin-4) Phase 1 Lacutamab Phase 2
Slide 17: IPH6501: Multiple Clinical Milestones to be Delivered in Mid-term
IPH6501: Multiple Clinical Milestones to be Delivered in Mid-term IPH6501 Phase 1/2 in B-NHL Safety data and preliminary Confirm activity and dose Readouts from signals of activity in CD20+ optimization in CD20+ B-NHL expansion studies in B-NHL & select B-NHL subtypes selected B-NHL subtypes (monoth
Slide 18: IPH4502 (Nectin-4 ADC): Multiple Clinical Milestones to be Delivered in Mid-term
ADC IPH4502 (Nectin-4 ADC): Multiple Clinical Milestones to be Delivered in Mid-term IPH4502 Phase 1 in Nectin-4 expressing tumors Start basket trial in combination with SOC Preliminary safety and activity signal in tumor types with low Readout from dose Dose FPI in Phase 1 and high Nectin-4 express
Slide 19: Lacutamab (KIR3DL2): Phase 3 ready proprietary asset with path to accelerated FDA approval
lacutamab Lacutamab (KIR3DL2): Phase 3 ready proprietary asset with path to accelerated FDA approval Lacutamab under development for treatment of First-in-class anti-KIR3DL2 humanized Cutaneous T-cell lymphomas (CTCL) and Peripheral T Cell Lymphomas (PTCL). cytotoxicity-inducing antibody Phase 2 dat
Slide 20: Lacutamab: Moving Towards Registrational Trial
lacutamab Lacutamab: Moving Towards Registrational Trial Phase 3 in CTCL BTD granted Phase 3 readout CTCL Partnership AA submission discussions 2025 2026 2027 + Phase 2 KILT in PTCL PTCL PTCL Phase 2 data Data will inform next steps 20 CTCL: cutaneous T cell lymphome; AA: accelerated approval; PTCL:
Slide 21: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts IPH6501 ANKET® (CD20 IL2v ANKET) | Phase 1 safety and preliminary efficacy data IPH6501 ANKET® (CD20 IL2v ANKET) | Phase 1 clinical data IPH6101 ANKET® (CD123) | Transfer to Innate ongoing Proprietary IPH4502 ADC (Nectin-4 ADC) | Phase 1 safety and preliminary IPH4502
Slide 22: Key Takeaways: Create value for patients and shareholders
Key Takeaways Create value for patients and shareholders Clinical stage company with growing differentiated first-in-class pipeline • EXPAND ANKET® CLINICAL PORTFOLIO • Phase 1/2 clinical trial underway with IPH6501, a proprietary 2nd generation CD20 ANKET® in B-cell NHL • IPH6101 (CD123 ANKET ®) tr
Slide 23: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA